| Gene symbol | TP53 | Synonyms | BCC7, BMFS5, LFS1, P53, TRP53 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17p13.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | tumor protein p53 | ||||
| GTO ID | GTC3458 |
| Trial ID | NCT05877599 |
| Disease | Head and Neck Squamous Cell Carcinoma | Breast Cancer | Pancreatic Adenocarcinoma | Colorectal Carcinoma | Lung Non-Small Cell Carcinoma |
| Altered gene | TP53 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NT-175|TP53 R175H TCR-T cells |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation |
| Year | 2023 |
| Country | United States |
| Company sponsor | Neogene Therapeutics, Inc. |
| Other ID(s) | NT-175-201 |
| Cohort 1 | |||||||||
|
|||||||||